NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Y-mAbs Therapeutics, Inc..
Shareholders who purchased shares of YMAB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/y-mabs-therapeutics-inc-loss-submission-form/?id=36299&from=4
CLASS PERIOD: This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ("FDA") willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.
DEADLINE: March 20, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/y-mabs-therapeutics-inc-loss-submission-form/?id=36299&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of YMAB during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 20, 2023. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-y-mabs-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-march-20-2023--nasdaq-ymab-301741405.html
SOURCE The Gross Law Firm
